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Box 81 Randwick, NSW 2031, Australia.Cluster of differentiation (CD) antigens are deﬁned when a surface molecule found on some mem-
bers of a standard panel of human cells reacts with at least one novel antibody, and there is good
accompanying molecular data. Monoclonal antibodies to surface CD antigens on leukocytes have
been used for ﬂow cytometry, and more recently to construct microarrays that capture live cells.
These DotScanTM microarrays enable the rapid and highly parallel characterization of repertoires
of CD antigens whose expression patterns may be correlated with discrete leukaemia subtypes, or
used to deﬁne biomarker ‘signatures’ for non-hematological diseases. DotScanTM with ﬂuorescence
multiplexing enables proﬁling of CD antigens for minor subsets of cells, such as colorectal cancer
cells and tumour-inﬁltrating lymphocytes from a surgical sample.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Surface proﬁling of leukaemias using DotScanTM
Human leukaemias may be classiﬁed as acute or chronic and are
derived from lymphoid or myeloid precursor cells. They are cur-
rently classiﬁed using multiple criteria including morphology,
karyotype, cytochemistry and a limited immunophenotype of
10–15 Cluster of differentiation (CD) antigens [1]. While ﬂow
cytometry is considered the ‘gold standard’ for identiﬁcation of
CD antigens expressed on the surface of leukocytes, only a limited
number of antigens can be identiﬁed in a single analysis. An alter-
native procedure involving capture of live cells by a microarray of
CD antibodies on a nitrocellulose ﬁlm (DotScanTM) has been devel-
oped that enables concurrent identiﬁcation of many CD antigens in
parallel (currently 82–147) [2]. In a clinical analysis involving 796
leukaemia patients and healthy control subjects, Belov et al. [3]chemical Societies. Published by E
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lia for Medical Research, P.O.demonstrated that surface proﬁles of multiple CD antigens ob-
tained from a DotScanTM microarray consisting of 82 monoclonal
antibodies with speciﬁcities directed against a range of different
CD antigens are sufﬁcient to classify leukaemias from samples of
peripheral blood (PB) or bone marrow aspirates (BMA). The classi-
ﬁcation of PB samples using DotScanTM showed a 93.9% correlation
with established criteria, and a 96.7% correlation with BMA, indi-
cating that an extensive immunophenotype alone is sufﬁcient to
classify the disease when a leukaemic clone dominates the cell
population. The extensive CD antigen immunophenotypes ob-
tained using highly parallel proteomic analysis on DotScanTM
may also have utility both as prognostic indicators and as predic-
tive biomarker signatures of clinical response to a speciﬁc thera-
peutic intervention.
2. Classiﬁcation of leukaemias
Flow cytometry using a limited surface immunophenotype
(10–15 CD antigens) comprises one of multiple criteria for the
diagnosis of human leukaemias. Cell surface proﬁling of CD anti-
gens is especially important in the diagnosis of acute lymphoblas-
tic leukaemia (ALL), helping to indicate the subtype of cell using
lineage-speciﬁc antigens and to distinguish undifferentiated acute
myeloid leukaemia (AML) from ALL [1]. Several groups have
investigated the possibility of diagnosing leukaemias based solely
upon immunophenotype [4,5]. Flow cytometry was used tolsevier B.V. All rights reserved.
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Flow cytometry is labour-intensive, expensive and enables paral-
lel measurement of only a small number of antigens. By contrast,
DotScanTM enables simultaneous and highly parallel screening of
many (currently 82–147) CD antigens, and this extensive surface
immuno-proﬁling appears sufﬁcient to classify most human leu-
kaemias. The CD antigens identiﬁed by the microarray correspond
well with those identiﬁed by ﬂow cytometry [2,3] although differ-
ent parameters are measured. In the case of ﬂow cytometry, the
ﬂuorescence intensity per cell is assessed on a gated population
of cells and compared with the level of ﬂuorescence for control
antibodies. For cell capture on an antibody microarray, there is a
threshold density of surface antigens sufﬁcient to provide stable
cell capture and the number of cells expressing a surface antigen
above that threshold density are quantiﬁed as the average density
of cells on each immobilized antibody dot. Monoclonal antibodies
immobilised on nitrocellulose may have reduced access to some
CD antigens expressed on the surface of live cells as compared
with the equivalent ﬂuorescently-labelled antibodies in free solu-
tion in ﬂow cytometry.
We have used DotScanTM to compile a database of mononuclear
leukocyte immunophenotypes from peripheral blood or bone
marrow aspirates derived from patients with a range of different
leukaemias [3]. AML comprises a number of diseases and other
groups have attempted to deﬁne AML sub-types using surface im-
muno-proﬁling. The best characterized subtype of AML is t(15;17)
or acute promyelocytic leukaemia (APL), with low or absent expres-
sion of CD11a, CD11b, CD18 and HLA-DR, with expression of CD9
and CD117 [6,7], consistent with the consensus proﬁle for APL
obtained using DotScanTM [3]. With more samples proﬁled, Dot-
ScanTM may provide a new classiﬁcation system for AML and other
leukaemias based solely on extensive immunophenotypes.Fig. 1. Dot patterns obtained from leukocytes captured on DotScanTM microarrays for nor
with acute myeloid leukaemia (AML). The numbers in the key refer to antibodies again
isotype control antibodies tested at the concentrations shown in lg/mL; TCR a/b, TCR c/d
DR, FMC-7, kappa and lambda immunoglobulin light chains and surface immunoglobulFig. 1 shows dot patterns obtained from cell capture on Dot-
ScanTM microarrays for normal mononuclear leukocytes from
peripheral blood, and a sample from a patient with AML in which
the AML cells are the predominant population. These dot patterns
may be transformed into cell surface CD antigen expression pro-
ﬁles using software that quantiﬁes the intensity of each dot
(Fig. 2). The principal differences between normal mononuclear
leukocytes and AML cells are clearly discernable, with AML show-
ing expression of the myeloid antigens CD13, CD15 and CD33 (red),
the stem cell (precursor) markers CD34 and CD117 (green) and a
range of other antigens, including aberrant expression of the T-cell
antigen CD4 (yellow). With lower grade leukaemias, the AML pat-
tern can generally still be distinguished from a background binding
pattern of normal leukocytes. However, when leukaemia cells
comprise less than 10% of the total population, a secondary detec-
tion system such as ﬂuorescent staining may be required to distin-
guish the leukaemia binding pattern.
DotScanTM has also been used to screen novel monoclonal anti-
bodies of undeﬁned CD antigen speciﬁcity submitted to the Human
Leukocyte Differentiation Antigen workshop (HLDA8) for their
reactivity with a panel of cell lines and patient samples. Antibody
binding patterns for around 75 cell types could be subjected to hier-
archical clustering to identifymonoclonal antibody clones that bind
to the same epitope [8]. DotScanTM is consequently able to provide a
rapid and reliable method for the screening and characterization of
the binding speciﬁcities of new monoclonal antibody clones.
3. Surface immuno-proﬁling of leukaemia samples from
peripheral blood and bone marrow
The populations of mononuclear leukocytes isolated by Hist-
opaque density gradient centrifugation from normal PB and BMAmal peripheral blood leukocytes (PBL) and a peripheral blood sample from a patient
st the corresponding CD antigens; mIgG1, mIgG2a, mIgG2b and mIgM are murine
, HLA-DR, FMC7, j, k and sIg are antibodies against T cell receptors a/b and c/d, HLA-
in, respectively. Mabthera is a humanized monoclonal antibody against CD20.
Fig. 2. Surface proﬁles obtained from the dot patterns in Fig. 1. The density of cell binding to each antibody above the background was calculated on an 8-bit pixel greyness
scale from 1 to 256 using DotScanTM software. Abbreviations: as for Fig. 1; Plt, platelets.
N. Barber et al. / FEBS Letters 583 (2009) 1785–1791 1787have cellular and immunophenotypic differences. The PB fraction is
principally mononuclear T- and B-lymphocytes and monocytes,
while the BMA fraction contains cells at various stages of differen-
tiation, mainly from themyeloid and B-lymphoid lineages [9]. Thus,
the background of normal leukocytes found in the mononuclear PB
and BMA fractions are distinct and yield different patterns when
analyzed using DotScanTM. The PB mononuclear fraction is com-
prised largely of T-lymphocytes (CD2, CD3, CD4, CD5, CD7, CD8,
TCRa/b), with lower levels of myeloid cells (mainly monocytic
CD13, CD14, CD64), B-lymphocytes (CD19, CD20, CD22, kappa
and lambda immunoglobulin light chains of surface immunoglobu-
lin) and contaminating platelets (CD41, CD42a, CD61, CD62P).
Mononuclear BMA fractions contain high levels of myeloid (neutro-
phil) precursors (e.g., CD13, CD15, CD16, CD24, CD43, CD45RO andFig. 3. CD antigen expression on control bone marrow and peripheral blood samples a
background was calculated on an 8-bit pixel greyness scale from 1 to 256 using DotScaCD66c [3]). This predominance of neutrophil precursors has been
conﬁrmed by ﬂow cytometry andmorphological analysis (N. Barber
and W. Sewell, unpublished results). Consequently, samples of leu-
kaemias in which the frequency of malignant clones is low (<10%
leukaemia cells) will contain a signiﬁcant proportion of non-malig-
nant cells that contribute to the expression proﬁle obtained from an
optical scan of the microarray. Comparison of low level leukaemic
surface proﬁles obtained with DotScanTM with equivalent normal
samples enables identiﬁcation of surface molecules that are differ-
entially abundant as a consequence of the pathological leukaemic
process. Fig. 3 shows the difference in surface proﬁles between nor-
mal samples from peripheral blood and bone marrow.
The binding patterns obtained for ‘high grade’ acute leukaemia
samples from PB and BMA (>10% leukaemia cells) are usuallys determined by DotScanTM. The density of cell binding to each antibody above the
nTM software. Abbreviations: as for Fig. 1; Plt, platelets.
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face CD117 (c-kit) from BMA compared with PB. For ALL, CD34 lev-
els were higher for precursor B-ALL from BMA compared with PB
[3]. These differences indicate that BMA samples contained a great-
er proportion of immature leukaemias; CD117 and CD34 expres-
sion is lost during maturation of myeloid (CD117 and CD34) and
lymphoid (CD34) cells. The surface proﬁles obtained for B-lympho-
proliferative disorders from PB and BMA samples were also similar.
For ‘high grade’ leukaemias (>107 leukaemia cells per mL), the
immunophenotype for a particular leukaemia will usually be sim-
ilar between PB and BMA. Weinkauff et al. [10] found that immun-
ophenotypes of PB and BMA blasts from the same patient analyzed
by ﬂow cytometry were similar; this observation should be con-
ﬁrmed using DotScanTM to determine whether there are site-spe-
ciﬁc homing, adhesion or other micro-environmental effects that
may be of biological importance. The extensive CD antigen surface
proﬁles obtained for leukaemias using DotScanTM are currently
being compiled in a database to enable more detailed subtyping,
to facilitate the prediction of patient responses to drugs and to de-
ﬁne prognosis at the individual patient level.
4. Proﬁling of leukaemias during differentiation therapy
4.1. All-trans retinoic acid
Drugs that induce differentiation of acute leukaemias may have
therapeutic beneﬁt by slowing growth. All-trans retinoic acid
(ATRA) is a successful anticancer drug used to treat acute promye-
locytic leukaemia (APL) [11] by inducing cells to differentiate intoFig. 4. Venn diagram comparing expression of CD antigens on differentiated HL-60 cells
neutrophils, (B) HL-60 cells treated with 1,25D3 compared with monocytes and (C) HL-60
Antigens in bold were tested on the DotScanTM microarray.‘abnormal’ granulocytes [12]. Initial studies demonstrated that 23/
24, 6/6 and 19/20 APL patients treated with ATRA achieved com-
plete remission [13–15]. The human cell line HL-60, is derived
from a case of the M2 subtype of AML and is used as a model for
drug-induced differentiation of promyelocytic leukaemia [16].
Drugs such as ATRA, 12-O-tetradecanoyl phorbol-13-acetate
(TPA) or 1-a,25-dihydroxyvitamin D3 (1,25D3) induce HL-60 cells
to differentiate into mature myeloid cells with loss of proliferative
capacity [17]. ATRA induces major changes in membrane proteins,
some of which are adhesion molecules that interact with neigh-
bouring cells. The clinically signiﬁcant and potentially fatal ‘reti-
noic acid syndrome’ may be due in part to interactions with
neighbouring cells resulting from the induction of adhesion mole-
cules and cytokines by ATRA [18]. We have used DotScanTM to ana-
lyze changes in CD antigen expression on HL-60 cells during
differentiation induced by ATRA [19].
ATRA induces differentiation of HL-60 into cells that resemble
neutrophils [20]. DotScanTM has been used to show that treatment
of HL-60 cells with ATRA induces CD11b, CD11c, CD36, CD38,
CD43, CD45RO, CD53, CD54, CD64 and CD66c and represses
CD29, CD44, CD95 and CD117 [19]. The Venn diagram of Fig. 4A
summarizes the expression of CD antigens on HL-60 cells treated
with ATRA as compared to the surface proﬁle obtained from nor-
mal neutrophils taken from the NCBI and PROW databases
[21,22]. The surface proﬁle of the neutrophil-like cells induced by
ATRA is not identical to that obtained from normal neutrophils.
HL-60 cells have activating mutations from their selection for cell
culture not present in healthy cells. However, ATRA-differentiated
HL-60 cells and normal neutrophils express a number of CD anti-with normal leukocyte subtypes. (A) HL-60 cells treated with ATRA compared with
cells treated with TPA compared with macrophages. Numbers indicate CD antigens.
Table 1
Functions of differentially expressed CD antigens on HL-60 cells induced by ATRA, 1,25D3 or TPA (Fig. 4). Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ma.,
macrophages; mo., monocytes; n., neutrophils; MC, mast cell, HPC, haematopoietic progenitor cell.
Antigen Expression Function Ref.
CD4 n., mo.,ma. Co-receptor for T-cell activation [23]
CD9 mo. Cell adhesion and migration [24]
CD11a n., mo., ma. Leukocyte adhesion and co-stimulation [25]
CD11b n., mo. Leukocyte adhesion [26]
CD11c n., mo., ma. Leukocyte adhesion [26]
CD13 n., mo., ma. Signalling [27]
CD14 mo., ma. Receptor for the Gram-negative bacterial endotoxin, lipopolysaccharide (LPS) and some
Gram-positive bacterial cell wall components
[28]
CD15 n., mo. Crucial for capture of the neutrophil by the endothelium before subsequent adhesive
interactions
[29]
CD16 n., mo., ma. Binds monomeric IgG and immune complexes and is involved in ADCC [30]
CD29 n., mo., ma. Adhesion and migration across extracellular matrix proteins [31]
CD31 n., mo., ma. Transendothelial migration and adhesion of neutrophils to macrophages [32]
CD36 mo., ma. Signalling [33]
CD38 mo. Acts with MHC Class II and FccRII to activate T-cells, cell adhesion [34]
CD43 n., mo., ma. Neutrophil movement [35]
CD44 n., mo., ma. Directed migration and polarisation of neutrophils and macrophages [36]
CD45 n., mo., ma. TCR and BCR mediated activation, neutrophil Fc receptor IIactivation, Fc receptor-
mediated ADCC
[26,37]
CD45R0 mo., ma. TCR and BCR mediated activation
CD49d mo. Cell adhesion [26]
CD49e mo. Cell adhesion [26]
CD53 n., mo., ma. Cell adhesion and migration [24]
CD54 n., mo., ma. Cell adhesion [38]
CD64 mo., ma. Facilitates MHC class I and class II-restricted antigen presentation to T-cells and mediates
phagocytosis and ADCC
[39]
CD66c n. Neutrophil adhesion, phagocytosis, and activation of superoxide production [40]
CD71 ma. Transferrin receptor [26]
CD86 mo. Co-regulator of T-cell activation with CD80 [41]
CD117 MC, HPC Growth factor receptor [26]
CD126 mo. Receptor for IL-6 involved in the immune response [42]
N. Barber et al. / FEBS Letters 583 (2009) 1785–1791 1789gens in common (Fig. 4A): CD4, CD11a, CD11b, CD11c, CD13, CD15,
CD29, CD31, CD33, CD43, CD44, CD45, CD45RO, CD53, CD54 and
CD66c. The functions of differentially expressed antigens on HL-
60 cells treated with ATRA are summarized in Table 1.
4.2. 1-a,25-dihydroxyvitamin D3
Although 1,25D3 induces differentiation of leukaemia cells,
therapeutic development has been limited due to hypercalcaemic
side-effects in vivo. A number of analogues of 1,25D3: EB1089,
MC903, RO24-5531, 1-a-hydroxyvitamin D2, 25-hydroxyvitamin
D3, 19-nor-1-a,25-dihydroxyvitamin D2 and 1-a-hydroxyvitamin
D5, induce differentiation without hypercalcaemia. These ana-
logues have passed stringent pre-clinical toxicity trials in animals
[43]. 1,25D3 induces differentiation of HL-60 cells to monocyte-like
cells with increased expression of CD14, CD11c, CD11b, CD54,
CD86, CD38 and CD66c, while CD117, CD71, CD95, CD45, CD64
and CD13 are repressed. Low levels of CD16, CD36 and CD126 were
also induced (Fig. 4B) [17]. The functions of these antigens are
summarized in Table 1.
4.3. 12-O-Tetradecanoyl phorbol-13-acetate
TPA was introduced into clinical trials in China [44] achieving a
reduction in bone marrow myeloblasts in 10 of 11 subjects with
AML. This success led to a Phase I clinical trial of TPA in the USA
with 14 patients [45]. Results of these trials indicate that TPA has
signiﬁcant clinical activity and that its toxicity proﬁle and efﬁcacy
warrant further development in a Phase 2 study. TPA induces dif-
ferentiation of HL-60 cells to macrophage-like cells with higher
expression levels of: CD11c, CD9, CD11b, CD54, CD38, CD45RO
and CD66c, while CD4 and CD117, CD95, CD71 and CD64 decrease
(Fig. 4C) [17].The surface proﬁles of the monocyte- and macrophage-like cells
induced by 1,25D3 and TPA, respectively, are not identical to those
obtained from normal monocytes and macrophages [17]. However,
Fig. 4B and C shows that normal monocytes and macrophages
share many CD antigens with HL-60 cells treated with 1,25D3 or
TPA. HL-60 cells treated with 1,25D3 express in common with
monocytes CD4, CD9, CD11a, CD11b, CD11c, CD13, CD14, CD15,
CD16, CD29, CD31, CD33, CD36, CD38, CD43, CD44, CD45, CD45RO,
CD49d, CD49e, CD54, CD64, CD86 and CD126. HL-60 cells treated
with TPA express in common with macrophages CD4, CD11a,
CD11c, CD13, CD29, CD31, CD43, CD44, CD45, CD45RO, CD54 and
CD64. The functions of differentially expressed antigens on HL-60
cells treated with 1,25D3 or TPA are summarized in Table 1.
5. Cytotoxic therapy with purine analogues
Purine nucleoside analogues are effective anticancer drugs that
are used in the treatment of B-lymphoproliferative disorders.
Cladribine (2-chloro-20-deoxyadenosine) is effective against some
cases of chronic lymphocytic leukaemia (CLL), low-grade non-
Hodgkin’s lymphoma and hairy cell leukaemia [46]. Cladribine as
the triphosphate derivative, inhibits ribonucleotide reductase and
DNA synthesis [47] resulting in apoptosis [48]. Fludarabine
(2-ﬂuoroarabinosyladenosine) is also active as the triphosphate
derivative with similar but not identical mechanisms of action to
cladribine, resulting in apoptosis [49] with activity against CLL
and indolent non-Hodgkin’s lymphoma [50].
Using DotScanTM, we have demonstrated that these purine
analogues induce changes in the levels of some CD antigens on
human MEC2 CLL and Raji Burkitt’s lymphoma cell lines (Gez,
Christopherson et al., manuscript in preparation). The effects of
ﬂudarabine nucleoside and cladribine (1 lM, 24 h) on cell surface
antigens on MEC2 and Raji cells have been determined using
1790 N. Barber et al. / FEBS Letters 583 (2009) 1785–1791DotScanTM. Raji cells treated with cladribine up-regulated by more
than 1.3-fold CD54, CD80, CD86 and CD95, with repression of
CD22, while ﬂudarabine nucleoside up-regulated CD20, CD54,
CD80, CD86 and CD95. MEC2 cells treated with cladribine up-reg-
ulated CD20, CD45, CD54, CD62L CD80, CD86 and CD95, but ﬂudar-
abine nucleoside had no effect.
6. Proﬁling of solid tumour phenotypes using ﬂuorescence
multiplexing
The cell surface CD antigen immuno-proﬁles presented here
have been derived from patient samples where the leukaemia
was predominant, or from monoclonal cell lines grown in culture.
Under these circumstances, an optical scan of the pattern of cap-
tured cells on DotScanTM provides an accurate surface proﬁle for
those cells. However, many (pathology) samples are heteroge-
neous, with the cancer cells in low proportion. To obtain a surface
proﬁle of only a subset of captured cells of interest, a procedure of
ﬂuorescence multiplexing has been developed for the analysis of
cell suspensions produced from surgical resections of colorectal
cancer (CRC) [51]. Cells were captured on the microarray, ﬁxed
with formalin and then stained with a mixture of ﬂuorescently-la-
belled soluble antibodies against chorio-embryonic antigen (CEA),
epithelial cell adhesion molecule (EpCAM) and CD3. The optical
scan of such a microarray had limited value because of the mixed
population of cells with the CRC cells in the minority. Fluorescent
scans for the soluble antibodies against CEA and EpCAM produced
dot patterns speciﬁc to CRC cells, while the scan for CD3 showed
the surface proﬁle for tumour-inﬁltrating lymphocytes (TILs). The
proﬁles obtained for the CRC cells dissected from the tumour were
compared with those derived from normal mucosa from the same
surgical sample to identify surface molecules differentially abun-
dant on CRC. The proﬁles obtained for T-lymphocytes (CD3) in
the CRC and normal mucosa fractions showed the presence of T-
cell activation markers in the cancer characteristic of TILs. These
proﬁles are being used to develop a new classiﬁcation system for
CRC, and some of the surface molecules identiﬁed may be potential
targets for development of therapeutic monoclonal antibodies.7. Conclusions
The DotScanTM antibody microarray enables the screening of
live cell suspensions for the expression of large numbers of cell
surface CD antigens in a single assay. The data obtained may be
used to classify leukaemias and other diseases based upon the pat-
terns of expression of cell surface CD antigens. Such proﬁles pro-
vide more robust results than classiﬁcations based upon the
presence of one or several disease markers. In a plenary lecture
at the ﬁrst international workshop on Human Leukocyte Differen-
tiation Antigens (HLDA1), Milstein (1984) speculated that the
‘‘complete deﬁnition of such mosaics” on cell surfaces would be
‘‘invaluable in deﬁning cells of varying differentiation and patho-
logical states”. While DotScanTM microarrays currently contain
antibodies against up to 147 cell surface CD antigens, a ‘full house’
microarray containing antibodies against all of the currently de-
ﬁned CD antigens (around 360) could easily be constructed. How-
ever, the precise size of the complete repertoire of cell surface CD
antigens expressed across the surface of cells from more than 200
different human tissues remains to be deﬁned. While HLDA9, to be
held in Barcelona in 2010, will certainly assign CD numbers to
more cell surface proteins, the numbers involved will remain well
below the total human complement. One of the criteria for desig-
nation as a CD antigen is the availability of several antibodies spe-
ciﬁc for extra-cellular epitopes of the protein. These monoclonal
antibody reagents are in the public domain and could be readilyincorporated into extended DotScanTM antibody microarrays as re-
quired. The application of CD antigen signatures is far broader than
just an application in human leukaemias and has the potential to
ultimately fulﬁl predictions made by Milstein (1984), namely the
extensive sub-phenotyping of normal and diseased cells using pat-
terns of cell surface CD antigen expression.
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